Cocrystal Pharma, Inc. (COCP): Price and Financial Metrics


Cocrystal Pharma, Inc. (COCP): $1.02

-0.04 (-3.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add COCP to Watchlist
Sign Up

Industry: Biotech


Ranked

of 503

in industry

COCP POWR Grades


  • COCP scores best on the Sentiment dimension, with a Sentiment rank ahead of 84.74% of US stocks.
  • The strongest trend for COCP is in Momentum, which has been heading down over the past 48 weeks.
  • COCP's current lowest rank is in the Momentum metric (where it is better than 4.41% of US stocks).

COCP Stock Summary

  • With a price/sales ratio of 102.44, Cocrystal Pharma Inc has a higher such ratio than 96.84% of stocks in our set.
  • As for revenue growth, note that COCP's revenue has grown -47.67% over the past 12 months; that beats the revenue growth of merely 5.12% of US companies in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for COCP comes in at -56.32% -- higher than that of only 4.86% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Cocrystal Pharma Inc are BBI, OMER, ARAV, SPRO, and LOGC.
  • Visit COCP's SEC page to see the company's official filings. To visit the company's web site, go to www.cocrystalpharma.com.

COCP Valuation Summary

  • In comparison to the median Healthcare stock, COCP's EV/EBIT ratio is 115.02% lower, now standing at -4.4.
  • Over the past 42 months, COCP's price/earnings ratio has gone down 9.
  • COCP's EV/EBIT ratio has moved down 3.3 over the prior 42 months.

Below are key valuation metrics over time for COCP.

Stock Date P/S P/B P/E EV/EBIT
COCP 2021-08-31 114.1 1.3 -10.6 -4.4
COCP 2021-08-30 108.3 1.3 -10.1 -3.9
COCP 2021-08-27 113.2 1.3 -10.5 -4.3
COCP 2021-08-26 115.1 1.4 -10.7 -4.5
COCP 2021-08-25 112.2 1.3 -10.5 -4.2
COCP 2021-08-24 114.1 1.3 -10.6 -4.4

COCP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • COCP has a Quality Grade of C, ranking ahead of 43.31% of graded US stocks.
  • COCP's asset turnover comes in at 0.016 -- ranking 376th of 677 Pharmaceutical Products stocks.
  • AGEN, COLL, and IBIO are the stocks whose asset turnover ratios are most correlated with COCP.

The table below shows COCP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.016 1 -32.893
2021-03-31 0.031 1 -23.294
2020-12-31 0.042 1 -18.512
2020-09-30 0.046 1 -178.742
2020-06-30 0.041 1 -114.668
2020-03-31 0.035 1 -61.369

COCP Price Target

For more insight on analysts targets of COCP, see our COCP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.33 Average Broker Recommendation 1.5 (Moderate Buy)

COCP Stock Price Chart Interactive Chart >

Price chart for COCP

COCP Price/Volume Stats

Current price $1.02 52-week high $3.46
Prev. close $1.05 52-week low $0.76
Day low $1.00 Volume 217,719
Day high $1.04 Avg. volume 8,050,481
50-day MA $1.10 Dividend yield N/A
200-day MA $1.37 Market Cap 98.93M

Cocrystal Pharma, Inc. (COCP) Company Bio


Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.


COCP Latest News Stream


Event/Time News Detail
Loading, please wait...

COCP Latest Social Stream


Loading social stream, please wait...

View Full COCP Social Stream

Latest COCP News From Around the Web

Below are the latest news stories about Cocrystal Pharma Inc that investors may wish to consider to help them evaluate COCP as an investment opportunity.

Cocrystal Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BOTHELL, Wash., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company, announces that management will present at the 23rd Annual Global Investment Conference being held September 13-15, 2021. A webcast of the presentation will be available on the IR Calendar of the Cocrystal Pharma website beginning at 1:00 a.m. Eastern time on Monday, September 13, 2021. “We look forward to discussing progress and milesto

Yahoo | September 7, 2021

Cocrystal Pharma, Inc. (COCP) Reports Q2 Loss, Misses Revenue Estimates

Cocrystal Pharma, Inc. (COCP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 16, 2021

Cocrystal Pharma Reports Second Quarter 2021 Financial Results and Provides Antiviral Program and Milestone Updates

Influenza program Phase 1 clinical trial with CC-42344 on track to begin in the third quarter of 2021COVID-19 program preclinical development with the novel oral SARS-CoV-2 protease inhibitors is advancingTwo IND-enabling studies in the COVID-19 program expected to begin in the first half of 2022 prior to Phase 1 clinical trials$67 million in cash at quarter-end is expected to fund current operations beyond 2024 BOTHELL, Wash., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: CO

Yahoo | August 16, 2021

California and NYC Order Mandatory COVID-19 Testing Among Municipal Workers

NEW YORK , Aug. 3, 2021 /PRNewswire/ -- New COVID-19 cases continue to surge throughout the United States , causing municipal governments to spring into action to combat the rising number of the highly infectious Delta variant cases. On Monday, California and New York City announced that they would require all government employees to get the coronavirus vaccine or face weekly COVID-19 testing. The White House also revealed that it would not be lifting international travel restrictions or re-opening US land borders to help combat the rising cases. With no clear end in sight to the ongoing pandemic, companies like Sixth Wave Innovations (CSE: SIXW ) (OTCQB: SIXWF ), Tonix Pharmaceuticals Holdings (NASDAQ: TNXP ), Vaxart (NASDAQ: VXRT ), Cocrystal Pharma Inc. (NASDAQ: COCP ) and Altimune (...

Benzinga | August 3, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We've got one more day of trading before the weekend so let's start it off with the biggest pre-market stock market movers for Friday.

William White on InvestorPlace | July 30, 2021

Read More 'COCP' Stories Here

COCP Price Returns

1-mo -4.67%
3-mo -23.88%
6-mo -27.14%
1-year -2.86%
3-year -63.31%
5-year -93.27%
YTD -25.00%
2020 174.47%
2019 -86.24%
2018 -40.00%
2017 -48.05%
2016 -56.74%

Continue Researching COCP

Here are a few links from around the web to help you further your research on Cocrystal Pharma Inc's stock as an investment opportunity:

Cocrystal Pharma Inc (COCP) Stock Price | Nasdaq
Cocrystal Pharma Inc (COCP) Stock Quote, History and News - Yahoo Finance
Cocrystal Pharma Inc (COCP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9187 seconds.